Camex Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:58 pm

Quick Insight

Camex Ltd, operating in the specialty chemicals sector, currently trades at a price of 37.2 with a market cap of 38.0 Cr. The company's P/E ratio stands at 16.9, indicating a moderate valuation. Despite a ROE of 4.63% and ROCE of 9.07%, which are below industry averages, Camex Ltd maintains a healthy OPM of 5.54%. With reserves of 33 Cr and minimal borrowings of ₹1 Cr, the company demonstrates a strong balance sheet. However, the low P/BV ratio of 0.71x suggests that the stock may be undervalued. Investors should closely monitor the company's operational efficiency and profitability to gauge future performance.

Competitors of Camex Ltd

All Competitor Stocks of Camex Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:37 am

Below is a detailed analysis of the quarterly data for Camex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 37.21 Cr.. The value appears strong and on an upward trend. It has increased from 28.21 Cr. (Dec 2024) to 37.21 Cr., marking an increase of 9.00 Cr..
• For Expenses, as of Mar 2025, the value is 35.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.58 Cr. (Dec 2024) to 35.15 Cr., marking an increase of 6.57 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.06 Cr.. The value appears strong and on an upward trend. It has increased from -0.37 Cr. (Dec 2024) to 2.06 Cr., marking an increase of 2.43 Cr..
• For OPM %, as of Mar 2025, the value is 5.54%. The value appears strong and on an upward trend. It has increased from -1.31% (Dec 2024) to 5.54%, marking an increase of 6.85%.
• For Other Income, as of Mar 2025, the value is -1.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.29 Cr. (Dec 2024) to -1.01 Cr., marking a decrease of 1.30 Cr..
• For Interest, as of Mar 2025, the value is 0.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.31 Cr. (Dec 2024) to 0.24 Cr., marking a decrease of 0.07 Cr..
• For Depreciation, as of Mar 2025, the value is 0.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Dec 2024) to 0.35 Cr., marking an increase of 0.26 Cr..
• For Profit before tax, as of Mar 2025, the value is 0.46 Cr.. The value appears strong and on an upward trend. It has increased from -0.48 Cr. (Dec 2024) to 0.46 Cr., marking an increase of 0.94 Cr..
• For Tax %, as of Mar 2025, the value is 69.57%. The value appears to be increasing, which may not be favorable. It has increased from -35.42% (Dec 2024) to 69.57%, marking an increase of 104.99%.
• For Net Profit, as of Mar 2025, the value is 0.15 Cr.. The value appears strong and on an upward trend. It has increased from -0.32 Cr. (Dec 2024) to 0.15 Cr., marking an increase of 0.47 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from -0.31 (Dec 2024) to 0.15, marking an increase of 0.46.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:24 pm

Balance Sheet

Last Updated: July 25, 2025, 1:38 pm

Below is a detailed analysis of the balance sheet data for Camex Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
• For Reserves, as of Mar 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2024) to 1.00 Cr., marking a decrease of 7.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 17.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13.00 Cr. (Mar 2024) to 17.00 Cr., marking an increase of 4.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 62.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2024) to 62.00 Cr., marking an increase of 1.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 8.00 Cr., marking an increase of 6.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 54.00 Cr.. The value appears to be declining and may need further review. It has decreased from 59.00 Cr. (Mar 2024) to 54.00 Cr., marking a decrease of 5.00 Cr..
• For Total Assets, as of Mar 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2024) to 62.00 Cr., marking an increase of 1.00 Cr..

Notably, the Reserves (33.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Camex Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 22, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 21) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 22, the value is 3.19. This value is below the healthy minimum of 5. It has increased from 1.37 (Mar 21) to 3.19, marking an increase of 1.82.
• For Diluted EPS (Rs.), as of Mar 22, the value is 3.19. This value is below the healthy minimum of 5. It has increased from 1.37 (Mar 21) to 3.19, marking an increase of 1.82.
• For Cash EPS (Rs.), as of Mar 22, the value is 3.97. This value is within the healthy range. It has increased from 2.27 (Mar 21) to 3.97, marking an increase of 1.70.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 38.95. It has increased from 33.24 (Mar 21) to 38.95, marking an increase of 5.71.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 22, the value is 38.95. It has increased from 33.24 (Mar 21) to 38.95, marking an increase of 5.71.
• For Revenue From Operations / Share (Rs.), as of Mar 22, the value is 175.58. It has increased from 147.10 (Mar 21) to 175.58, marking an increase of 28.48.
• For PBDIT / Share (Rs.), as of Mar 22, the value is 2.98. This value is within the healthy range. It has decreased from 3.36 (Mar 21) to 2.98, marking a decrease of 0.38.
• For PBIT / Share (Rs.), as of Mar 22, the value is 2.12. This value is within the healthy range. It has decreased from 2.43 (Mar 21) to 2.12, marking a decrease of 0.31.
• For PBT / Share (Rs.), as of Mar 22, the value is 3.99. This value is within the healthy range. It has increased from 1.75 (Mar 21) to 3.99, marking an increase of 2.24.
• For Net Profit / Share (Rs.), as of Mar 22, the value is 3.12. This value is within the healthy range. It has increased from 1.33 (Mar 21) to 3.12, marking an increase of 1.79.
• For NP After MI And SOA / Share (Rs.), as of Mar 22, the value is 3.08. This value is within the healthy range. It has increased from 1.33 (Mar 21) to 3.08, marking an increase of 1.75.
• For PBDIT Margin (%), as of Mar 22, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.28 (Mar 21) to 1.69, marking a decrease of 0.59.
• For PBIT Margin (%), as of Mar 22, the value is 1.20. This value is below the healthy minimum of 10. It has decreased from 1.65 (Mar 21) to 1.20, marking a decrease of 0.45.
• For PBT Margin (%), as of Mar 22, the value is 2.27. This value is below the healthy minimum of 10. It has increased from 1.19 (Mar 21) to 2.27, marking an increase of 1.08.
• For Net Profit Margin (%), as of Mar 22, the value is 1.77. This value is below the healthy minimum of 5. It has increased from 0.90 (Mar 21) to 1.77, marking an increase of 0.87.
• For NP After MI And SOA Margin (%), as of Mar 22, the value is 1.75. This value is below the healthy minimum of 8. It has increased from 0.90 (Mar 21) to 1.75, marking an increase of 0.85.
• For Return on Networth / Equity (%), as of Mar 22, the value is 8.46. This value is below the healthy minimum of 15. It has increased from 4.00 (Mar 21) to 8.46, marking an increase of 4.46.
• For Return on Capital Employeed (%), as of Mar 22, the value is 4.46. This value is below the healthy minimum of 10. It has decreased from 5.95 (Mar 21) to 4.46, marking a decrease of 1.49.
• For Return On Assets (%), as of Mar 22, the value is 4.83. This value is below the healthy minimum of 5. It has increased from 1.68 (Mar 21) to 4.83, marking an increase of 3.15.
• For Long Term Debt / Equity (X), as of Mar 22, the value is 0.22. This value is within the healthy range. It has increased from 0.20 (Mar 21) to 0.22, marking an increase of 0.02.
• For Total Debt / Equity (X), as of Mar 22, the value is 0.23. This value is within the healthy range. It has decreased from 0.51 (Mar 21) to 0.23, marking a decrease of 0.28.
• For Asset Turnover Ratio (%), as of Mar 22, the value is 2.29. It has increased from 2.16 (Mar 21) to 2.29, marking an increase of 0.13.
• For Current Ratio (X), as of Mar 22, the value is 3.74. This value exceeds the healthy maximum of 3. It has increased from 1.85 (Mar 21) to 3.74, marking an increase of 1.89.
• For Quick Ratio (X), as of Mar 22, the value is 2.91. This value exceeds the healthy maximum of 2. It has increased from 1.45 (Mar 21) to 2.91, marking an increase of 1.46.
• For Inventory Turnover Ratio (X), as of Mar 22, the value is 3.32. This value is below the healthy minimum of 4. It has decreased from 3.77 (Mar 21) to 3.32, marking a decrease of 0.45.
• For Interest Coverage Ratio (X), as of Mar 22, the value is 2.34. This value is below the healthy minimum of 3. It has decreased from 4.98 (Mar 21) to 2.34, marking a decrease of 2.64.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 22, the value is 0.98. This value is below the healthy minimum of 3. It has decreased from 2.97 (Mar 21) to 0.98, marking a decrease of 1.99.
• For Enterprise Value (Cr.), as of Mar 22, the value is 35.37. It has decreased from 36.38 (Mar 21) to 35.37, marking a decrease of 1.01.
• For EV / Net Operating Revenue (X), as of Mar 22, the value is 0.19. This value is below the healthy minimum of 1. It has decreased from 0.24 (Mar 21) to 0.19, marking a decrease of 0.05.
• For EV / EBITDA (X), as of Mar 22, the value is 11.63. This value is within the healthy range. It has increased from 10.59 (Mar 21) to 11.63, marking an increase of 1.04.
• For MarketCap / Net Operating Revenue (X), as of Mar 22, the value is 0.14. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 21) to 0.14, marking an increase of 0.01.
• For Price / BV (X), as of Mar 22, the value is 0.71. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 21) to 0.71, marking an increase of 0.12.
• For Price / Net Operating Revenue (X), as of Mar 22, the value is 0.14. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 21) to 0.14, marking an increase of 0.01.
• For EarningsYield, as of Mar 22, the value is 0.11. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 21) to 0.11, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness